Hormonal
GLP-1 receptor agonists (specifically semaglutide 2.4 mg and liraglutide 3.0 mg) are the most effective pharmacotherapeutic interventions for weight loss in adults with obesity, significantly outperforming placebo and other agents.
For adults with obesity, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are the most effective medication options for weight loss, producing significantly greater weight reduction than placebo or other drugs. While gastrointestinal side effects like nausea are common, the overall safety profile is favorable, making these a promising treatment option when lifestyle changes alone are insufficient.
Glucagon-like peptide-1 (GLP-1) receptor agonists showed the highest efficacy... Semaglutide 2.4 mg has shown statistically significant weight reduction over placebo after 104 weeks (–16.7% (0.9) with semaglutide and –0.6% (0.9) for placebo)... Once-weekly subcutaneous semaglutide has also been shown to be superior to once-daily subcutaneous liraglutide... mean weight change from baseline was -15.8% with semaglutide, whereas it was -6.4% with liraglutide
Why this rating
Based on a systematic review of 35 articles including RCTs and meta-analyses, though the review itself notes limitations in study designs.
Source
Pharmacotherapeutics efficacy in obesity treatment: A systematic review
Tarboush BA et al. · International Journal of Advanced Community Medicine · 2023
DOI 10.33545/comed.2023.v6.i1a.256
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →